This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the …

All therapies currently recommended for the management of osteoporosis act mainly to
inhibit bone resorption and reduce bone remodeling. PTH and its analog, teriparatide […

Background Long-term safety and efficacy of osteoporosis treatment are important because
of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of …

Background and Methods Osteoporosis is a recognized complication of corticosteroid
therapy. Whether it can be prevented is not known. We conducted a 12-month, randomized, …

The International Society for Clinical Densitometry (ISCD) periodically convenes Position
Development Conferences (PDCs) in order to establish standards and guidelines for the …

The amino-bisphosphonates are first-line therapy for the treatment of most patients with
osteoporosis, with proven efficacy to reduce fracture risk at the spine, hip, and other nonvertebral …

Context: Denosumab treatment for 24 months increased bone mineral density (BMD) and
reduced bone turnover markers (BTM) in postmenopausal women. Objective: The aim was to …

Patients treated with bisphosphonates for osteoporosis may discontinue or require a switch
to other therapies. Denosumab binds to RANKL and is a potent inhibitor of bone resorption …

The International Society for Clinical Densitometry (ISCD) convenes a Position Development
Conference (PDC) every 2yr to make recommendations for standards in the field of bone …

Background No clinical trials have compared osteoporosis drugs with incident fractures as
the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in …